Vaccine Adjuvants Market worth $1.6 billion by 2027 | Growth Drivers & Opportunities

Vaccine Adjuvants Market is projected to grow from USD 1.5 billion in 2022 to USD 1.6 billion by 2027, at a CAGR of 1.7% from 2022 to 2027, according to a new report by MarketsandMarkets™. The growth of the market is projected to be driven by collaborations and partnerships among market players for the development of vaccine adjuvants, an increasing number of COVID-19 vaccines in the development pipeline and increasing focus on immunization programs.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

Browse in-depth TOC on “Vaccine Adjuvants Market”

191 – Tables

44 – Figures

214 – Pages

Key Market Players

The global vaccine adjuvants market is highly competitive. The prominent players operating in this market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), Vaxine Pty Ltd. (Australia), Creative Diagnostics (US), LiteVax BV (Netherlands), Mukta Industries (India), Oncovir, Inc. (US), and TiterMax USA, Inc. (US). Product launch, partnerships, collaborations and geographic expansion are the key growth strategies undertaken by these companies to maintain their positions in the market.

GSK plc (UK)

GlaxoSmithKline (UK) held the leading position in the market in 2021. The company has entered into collaborations and partnerships with a number of vaccine developers and is recognized for its contrition in the COVID-19 space. SK Bioscience (South Korea), Bharat Biotech International Limited (India), and Government of Canada (Canada) are some of the major partners of the company.

Dynavax Technologies (US)

Dynavax focuses on inorganic growth strategies to maintain its market position. Biological E Limited (India), Clover Biopharmaceuticals (China), Valneva SE (France), and Medigen Vaccine Biologics (China) are some of the company’s partners in vaccine development.

Novavax (US)

Novavax is also one of the leading players in the vaccine adjuvants market. The company focuses on inorganic growth strategies such as partnerships to strengthen its market position. The company partnered with AGC Biologics (Denmark) and Serum Institute of India (India) for the development of vaccines for COVID-19 and malaria.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets of the region is drive by increasing investments in the life sciences sector and rising awareness through conferences & symposiums, and growing emphasis on strategic initiatives such as partnerships, and collaborations by biopharma and biotech companies.

Recent Developments

• Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
• SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Article source: https://article-realm.com/article/Health-Fitness/Exercise/41082-Vaccine-Adjuvants-Market-worth-1-6-billion-by-2027-Growth-Drivers-and-Opportunities.html